BlackThorn Therapeutics bring in new CEO
BlackThorn Therapeutics, a biopharmaceutical company that works on developing treatments for neurobehavioral disorders, announced the appointment of Gregory Vontz to the position of Chief Executive Officer.
Vontz’s previous role was as President and Chief Executive Officer of Topica Pharmaceuticals, a position he held for nine years. Prior to this, he worked as President and Chief Operating Officer at Connetics Corporation for seven years. He also has 12 years’ experience working as Director of Cardiovascular Marketing at Genentech.
“I am excited to join the outstanding team at BlackThorn as it develops a pipeline of targeted treatments that modulate the brain physiology responsible for neurobehaviorial disorders,” said Mr. Vontz. “With the closing of our $54 million Series A funding, we are well positioned to advance our INFORM platform which guides the company’s portfolio of first-in-class small molecules and clinical development programs targeting significant neurobehaviorial disorders. I look forward to building the company and working with the team to achieve our goal of becoming the leading neurobehavioral health company.”
“On behalf of the Board and the BlackThorn team, I am pleased to welcome Greg as our new chief executive officer,” said Dr. Corrigan, BlackThorn Chairman of the Board. “His experience as a biotech executive, record of successful drug development and strategic transactions will serve BlackThorn well in advancing the company’s mission to develop new treatments for patients suffering from neurobehavioral disorders.”